Company Overview and News
KUALA LUMPUR (Aug 10): Datasonic Group Bhd shares rose 1.21% at mid-morning today after the company said it is partnering Bahraini company Dynamic Structures WLL (DSWLL) to expand its security business internationally in 18 countries in the Middle East and North Africa (MENA) region.
KUALA LUMPUR (Aug 9): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Supermax Corp Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Sunway Real Estate Investment Trust, Bintai Kinden Corp Bhd, Far East Holdings Bhd, Datasonic Group Bhd, Velesto Energy Bhd, Barakah Offshore Petroleum Bhd, My EG Services Bhd, Ranhill Holdings Bhd, Asdion Bhd and IHH Healthcare Bhd.
7251 SPMXF 5176 5272 532843 5843 5029 5216 SPMXY 5225 FORTIS Q0F IHHHF
KUALA LUMPUR (Aug 9): Datasonic Group Bhd is partnering Bahraini company Dynamic Structures WLL (DSWLL) to expand its security business internationally in 18 countries in the Middle East and North Africa (MENA) region.
KUALA LUMPUR (Aug 1): Based on corporate announcements and news flow today, companies in focus on Thursday (Aug 2) may include: DRB-Hicom Bhd, Malakoff Corp Bhd, Borneo Aqua Harvest Bhd, Boustead Plantations Bhd, LKL International Bhd, Malaysia Marine and Heavy Engineering Holdings Bhd, Ann Joo Resources Bhd, Utusan Melayu (Malaysia) Bhd, Poly Glass Fibre (M) Bhd, Datasonic Group Bhd, Apex Equity Holdings Bhd and AirAsia Group Bhd.
5216 5754 6556 5088 MYPRY 8117 5014 0098 5254
KUALA LUMPUR (Aug 1): Datasonic Group Bhd said today the ongoing lawsuit between its wholly-owned unit Datasonic Technologies Sdn Bhd (DTSB) and Percetakan Keselamatan Nasional Sdn Bhd (PKN), a wholly-owned subsidiary of Fima Corp Bhd, will not affect its five-year contract with the government to supply Malaysian passport booklets.
5216 BSMAF 1818
KUALA LUMPUR: Datasonic Group Bhd believes it has a good defence against Fima Corp Bhd ’s legal action to claim RM24.98mil from the company.
KUALA LUMPUR (Aug 1): The FBM KLCI is seen starting off August on a positive note today, in line with the overnight gains at most global markets, with support at the 1,770-point level.
5436 5216 0035 7158 5151 7022 GBTKF
KUALA LUMPUR (July 31): Based on corporate announcements and news flow today, companies in focus on Wednesday (Aug 1) may include: Scomi Group Bhd, YTL Hospitality Real Estate Investment Trust (REIT), Serba Dinamik Holdings Bhd, Perusahaan Sadur Timah Malaysia Bhd, Globetronics Technology Bhd, Opcom Holdings Bhd, Halex Holdings Bhd and Datasonic Group Bhd.
SLLXF 5436 5216 4863 0035 5109 7158 HIL MYTEF 5151 7022 GBTKF
KUALA LUMPUR (July 31): Datasonic Group Bhd said today that its unit has yet to receive a writ of summons from Fima Corp Bhd's subsidiary Percetakan Keselamatan Nasional Sdn Bhd (PKN) on a lawsuit claim for RM24.98 million in alleged unpaid dues.
5216 BSMAF 1818
KUALA LUMPUR (July 31): Shares in Datasonic Group Bhd fell as much as 5.2% or 4.5 sen this morning, as a recent lawsuit and a lawmaker's call to review existing national identity cards ushered in a new wave of uncertainty over the counter.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...